vs

Side-by-side financial comparison of AvalonBay Communities (AVB) and Lantheus Holdings, Inc. (LNTH). Click either name above to swap in a different company.

AvalonBay Communities is the larger business by last-quarter revenue ($767.9M vs $406.8M, roughly 1.9× Lantheus Holdings, Inc.). AvalonBay Communities runs the higher net margin — 9040.6% vs 13.3%, a 9027.3% gap on every dollar of revenue. On growth, Lantheus Holdings, Inc. posted the faster year-over-year revenue change (4.0% vs 3.7%). AvalonBay Communities produced more free cash flow last quarter ($1.4B vs $81.4M). Over the past eight quarters, Lantheus Holdings, Inc.'s revenue compounded faster (4.9% CAGR vs 3.8%).

AvalonBay Communities, Inc. is a publicly traded real estate investment trust that invests in apartments.

Lantheus Holdings, Inc. is a global healthcare firm specializing in the development, manufacturing and commercialization of innovative diagnostic imaging agents and related solutions. Its offerings cover core medical segments including oncology, cardiology and urology, with primary markets across North America and other key global regions.

AVB vs LNTH — Head-to-Head

Bigger by revenue
AVB
AVB
1.9× larger
AVB
$767.9M
$406.8M
LNTH
Growing faster (revenue YoY)
LNTH
LNTH
+0.3% gap
LNTH
4.0%
3.7%
AVB
Higher net margin
AVB
AVB
9027.3% more per $
AVB
9040.6%
13.3%
LNTH
More free cash flow
AVB
AVB
$1.3B more FCF
AVB
$1.4B
$81.4M
LNTH
Faster 2-yr revenue CAGR
LNTH
LNTH
Annualised
LNTH
4.9%
3.8%
AVB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AVB
AVB
LNTH
LNTH
Revenue
$767.9M
$406.8M
Net Profit
$166.0M
$54.1M
Gross Margin
59.2%
Operating Margin
64.2%
19.0%
Net Margin
9040.6%
13.3%
Revenue YoY
3.7%
4.0%
Net Profit YoY
-41.2%
558.8%
EPS (diluted)
$1.18
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVB
AVB
LNTH
LNTH
Q4 25
$767.9M
$406.8M
Q3 25
$766.8M
$384.0M
Q2 25
$760.2M
$378.0M
Q1 25
$745.9M
$372.8M
Q4 24
$740.5M
$391.1M
Q3 24
$734.3M
$378.7M
Q2 24
$726.0M
$394.1M
Q1 24
$712.9M
$370.0M
Net Profit
AVB
AVB
LNTH
LNTH
Q4 25
$166.0M
$54.1M
Q3 25
$381.3M
$27.8M
Q2 25
$268.7M
$78.8M
Q1 25
$236.6M
$72.9M
Q4 24
$282.1M
$-11.8M
Q3 24
$372.5M
$131.1M
Q2 24
$253.9M
$62.1M
Q1 24
$173.4M
$131.1M
Gross Margin
AVB
AVB
LNTH
LNTH
Q4 25
59.2%
Q3 25
57.9%
Q2 25
63.8%
Q1 25
63.8%
Q4 24
63.5%
Q3 24
63.9%
Q2 24
64.9%
Q1 24
65.4%
Operating Margin
AVB
AVB
LNTH
LNTH
Q4 25
64.2%
19.0%
Q3 25
65.7%
11.4%
Q2 25
67.6%
23.3%
Q1 25
68.5%
27.4%
Q4 24
63.1%
29.1%
Q3 24
65.4%
35.3%
Q2 24
66.6%
26.1%
Q1 24
67.2%
28.8%
Net Margin
AVB
AVB
LNTH
LNTH
Q4 25
9040.6%
13.3%
Q3 25
49.7%
7.2%
Q2 25
35.3%
20.8%
Q1 25
31.7%
19.6%
Q4 24
38.1%
-3.0%
Q3 24
50.7%
34.6%
Q2 24
35.0%
15.8%
Q1 24
24.3%
35.4%
EPS (diluted)
AVB
AVB
LNTH
LNTH
Q4 25
$1.18
$0.86
Q3 25
$2.68
$0.41
Q2 25
$1.88
$1.12
Q1 25
$1.66
$1.02
Q4 24
$1.99
$-0.18
Q3 24
$2.61
$1.79
Q2 24
$1.78
$0.88
Q1 24
$1.22
$1.87

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVB
AVB
LNTH
LNTH
Cash + ST InvestmentsLiquidity on hand
$187.2M
$359.1M
Total DebtLower is stronger
$9.3B
$568.7M
Stockholders' EquityBook value
$11.6B
$1.1B
Total Assets
$22.2B
$2.2B
Debt / EquityLower = less leverage
0.80×
0.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVB
AVB
LNTH
LNTH
Q4 25
$187.2M
$359.1M
Q3 25
$123.3M
$382.0M
Q2 25
$102.8M
$695.6M
Q1 25
$53.3M
$938.5M
Q4 24
$108.6M
$912.8M
Q3 24
$552.4M
$866.4M
Q2 24
$545.8M
$757.0M
Q1 24
$287.9M
$718.3M
Total Debt
AVB
AVB
LNTH
LNTH
Q4 25
$9.3B
$568.7M
Q3 25
$8.7B
$567.9M
Q2 25
$8.7B
$566.8M
Q1 25
$8.3B
$566.1M
Q4 24
$8.1B
$565.3M
Q3 24
$8.4B
$613.0K
Q2 24
$8.4B
$563.2M
Q1 24
$8.0B
$562.5M
Stockholders' Equity
AVB
AVB
LNTH
LNTH
Q4 25
$11.6B
$1.1B
Q3 25
$11.9B
$1.1B
Q2 25
$11.9B
$1.2B
Q1 25
$11.9B
$1.2B
Q4 24
$11.9B
$1.1B
Q3 24
$11.9B
$1.2B
Q2 24
$11.7B
$1.0B
Q1 24
$11.7B
$945.5M
Total Assets
AVB
AVB
LNTH
LNTH
Q4 25
$22.2B
$2.2B
Q3 25
$21.9B
$2.3B
Q2 25
$21.8B
$2.1B
Q1 25
$21.2B
$2.1B
Q4 24
$21.0B
$2.0B
Q3 24
$21.3B
$2.0B
Q2 24
$21.0B
$1.9B
Q1 24
$20.6B
$1.8B
Debt / Equity
AVB
AVB
LNTH
LNTH
Q4 25
0.80×
0.52×
Q3 25
0.73×
0.51×
Q2 25
0.72×
0.49×
Q1 25
0.70×
0.49×
Q4 24
0.68×
0.52×
Q3 24
0.70×
0.00×
Q2 24
0.71×
0.55×
Q1 24
0.68×
0.59×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVB
AVB
LNTH
LNTH
Operating Cash FlowLast quarter
$1.7B
$90.2M
Free Cash FlowOCF − Capex
$1.4B
$81.4M
FCF MarginFCF / Revenue
183.5%
20.0%
Capex IntensityCapex / Revenue
34.1%
2.2%
Cash ConversionOCF / Net Profit
10.07×
1.67×
TTM Free Cash FlowTrailing 4 quarters
$2.5B
$354.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVB
AVB
LNTH
LNTH
Q4 25
$1.7B
$90.2M
Q3 25
$477.0M
$105.3M
Q2 25
$377.8M
$87.1M
Q1 25
$415.9M
$107.6M
Q4 24
$1.6B
$157.7M
Q3 24
$486.2M
$175.1M
Q2 24
$380.0M
$84.7M
Q1 24
$412.9M
$127.2M
Free Cash Flow
AVB
AVB
LNTH
LNTH
Q4 25
$1.4B
$81.4M
Q3 25
$402.2M
$94.7M
Q2 25
$317.1M
$79.1M
Q1 25
$367.5M
$98.8M
Q4 24
$1.4B
$141.4M
Q3 24
$434.2M
$159.3M
Q2 24
$333.0M
$73.5M
Q1 24
$375.4M
$119.0M
FCF Margin
AVB
AVB
LNTH
LNTH
Q4 25
183.5%
20.0%
Q3 25
52.5%
24.7%
Q2 25
41.7%
20.9%
Q1 25
49.3%
26.5%
Q4 24
191.0%
36.1%
Q3 24
59.1%
42.0%
Q2 24
45.9%
18.7%
Q1 24
52.7%
32.2%
Capex Intensity
AVB
AVB
LNTH
LNTH
Q4 25
34.1%
2.2%
Q3 25
9.8%
2.8%
Q2 25
8.0%
2.1%
Q1 25
6.5%
2.3%
Q4 24
26.1%
4.2%
Q3 24
7.1%
4.2%
Q2 24
6.5%
2.8%
Q1 24
5.3%
2.2%
Cash Conversion
AVB
AVB
LNTH
LNTH
Q4 25
10.07×
1.67×
Q3 25
1.25×
3.79×
Q2 25
1.41×
1.11×
Q1 25
1.76×
1.47×
Q4 24
5.70×
Q3 24
1.31×
1.34×
Q2 24
1.50×
1.36×
Q1 24
2.38×
0.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AVB
AVB

Segment breakdown not available.

LNTH
LNTH

Radiopharmaceutical Oncology$240.2M59%
Definity$85.3M21%
Strategic Partnerships And Other$23.3M6%
Techne Lite$21.0M5%
Licenseand Royalty Revenues$17.4M4%
Other$13.6M3%
Other Precision Diagnostics$5.9M1%

Related Comparisons